ID KAK-1 AC CVCL_6301 SY KAK1; KAK DR BioSample; SAMN03151788 DR cancercelllines; CVCL_6301 DR Cosmic; 886555 DR Cosmic; 888090 DR Cosmic; 913245 DR Wikidata; Q54899461 RX PubMed=9177396; RX PubMed=11439348; RX PubMed=17804723; RX PubMed=18713817; RX PubMed=20143388; WW Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx CC Problematic cell line: Contaminated. Shown to be a HT-29 derivative (PubMed=18713817; PubMed=20143388). Originally thought to originate from a thyroid gland follicular carcinoma. CC Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00220. CC Population: Caucasian. CC Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Glu853Ter (c.2557G>T); ClinVar=VCV001071632; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:583; APC; Simple; p.Thr1556Asnfs*3 (c.4666dupA) (c.4666_4667insA); ClinVar=VCV000428112; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:8975; PIK3CA; Simple; p.Pro449Thr (c.1345C>A); ClinVar=VCV001333250; Zygosity=Heterozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:6770; SMAD4; Simple; p.Gln311Ter (c.931C>T); ClinVar=VCV000230663; Zygosity=Homozygous (from parent cell line). CC Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Homozygous (from parent cell line). CC Omics: Transcriptomics; Microarray. CC Derived from site: In situ; Colon; UBERON=UBERON_0001155. DI NCIt; C4349; Colon adenocarcinoma OX NCBI_TaxID=9606; ! Homo sapiens (Human) HI CVCL_0320 ! HT-29 SX Female AG 44Y CA Cancer cell line DT Created: 04-04-12; Last updated: 10-04-25; Version: 30 // RX PubMed=20143388; DOI=10.1002/ijc.25242; RA Capes-Davis, Amanda RA Theodosopoulos, George RA Atkin, Isobel RA Drexler, Hans Gunther RA Kohara, Arihiro RA MacLeod, Roderick A.F. RA Masters, John R.W. RA Nakamura, Yukio RA Reid, Yvonne A. RA Reddel, Roger Robert RA Freshney, Robert Ian RT "Check your cultures! A list of cross-contaminated or misidentified RT cell lines."; RL Int. J. Cancer 127:1-8(2010). // RX PubMed=18713817; DOI=10.1210/jc.2008-1102; PMCID=PMC2582569; RA Schweppe, Rebecca E. RA Klopper, Joshua P. RA Korch, Christopher T. RA Pugazhenthi, Umarani RA Benezra, Miriam RA Knauf, Jeffrey A. RA Fagin, James Alexander RA Marlow, Laura A. RA Copland, John Alton 3rd RA Smallridge, Robert Christian RA Haugen, Bryan R. RT "Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer RT cell lines reveals cross-contamination resulting in cell line RT redundancy and misidentification."; RL J. Clin. Endocrinol. Metab. 93:4331-4341(2008). // RX PubMed=17804723; DOI=10.1158/0008-5472.CAN-06-4026; RA van Staveren, Wilma C.G. RA Weiss-Solis, David Y. RA Delys, Laurent RA Duprez, Laurence RA Andry, Guy RA Franc, Brigitte RA Thomas, Gerry RA Libert, Frederick RA Dumont, Jacques-Emile RA Detours, Vincent RA Maenhaut, Carine RT "Human thyroid tumor cell lines derived from different tumor types RT present a common dedifferentiated phenotype."; RL Cancer Res. 67:8113-8120(2007). // RX PubMed=11439348; DOI=10.1038/sj.onc.1204531; RA Frasca, Francesco RA Vigneri, Paolo RA Vella, Veronica RA Vigneri, Riccardo RA Wang, Jean Y.-J. RT "Tyrosine kinase inhibitor STI571 enhances thyroid cancer cell motile RT response to hepatocyte growth factor."; RL Oncogene 20:3845-3856(2001). // RX PubMed=9177396; DOI=10.1210/jcem.82.6.4013; RA Ain, Kenneth B. RA Taylor, Kimberly D. RA Tofiq, Sharmen RA Venkataraman, Gopalakrishnan RT "Somatostatin receptor subtype expression in human thyroid and thyroid RT carcinoma cell lines."; RL J. Clin. Endocrinol. Metab. 82:1857-1862(1997). //